S&P 500 E-Mini Sep '16 (ESU16)

Intellia Therapeutics announces positive Phase 1 trial results for nex-z in ATTR amyloidosis, indicating significant TTR reduction and disease stabilization.Quiver AI SummaryIntellia Therapeutics announced...

Cytokinetics presented new analyses on omecamtiv mecarbil's efficacy in heart failure at the AHA Scientific Sessions 2024.Quiver AI SummaryCytokinetics, Incorporated announced new findings from post-hoc...

New analyses show Aficamten improves oxygen uptake recovery, quality of life, and reduces septal reduction therapy eligibility in HCM patients.Quiver AI SummaryCytokinetics, Incorporated announced new...

Nuclear stocks are gaining momentum, and Vistra is leading the charge. With investments in zero-carbon assets and a bullish outlook from analysts, the company is capitalizing on the nuclear sector's resurgence...

With Realty Income’s shares lagging behind the broader market over the past year, Wall Street analysts remain cautiously optimistic about its prospects.

Although CELH stock will likely represent a long-term value play, temporary uncertainties over the beverage industry present a compelling short trade.

What’s behind this analyst’s sudden shift to a more cautious stance on Devon Energy?

Estée Lauder has significantly underperformed the broader market over the past year, and Wall Street analysts maintain a neutral stance on the stock’s future prospects.

PPL Corporation has surpassed the broader market's performance this year, with analysts expressing a cautiously optimistic outlook for the stock's future prospects.

Although Target has underperformed the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook for the stock’s future potential.